MedPath

The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.

Completed
Conditions
Neuroendocrine Tumours (NETs)
Mediterranean Diet
Registration Number
NCT03592940
Lead Sponsor
Federico II University
Brief Summary

Nutritional status in patients with neuroendocrine tumours (NETs), especially of gastroenteropancreatic origin, can be deeply affected by excessive production of gastrointestinal hormones, peptides, and amines, which can lead to malabsorption, diarrhoea, steatorrhea, and altered gastrointestinal motility. Besides, the surgical and/or medical management of NETs can lead to alteration of gastrointestinal secretory, motor, and absorptive functions, with both dietary and nutritional consequences. Indeed, disease-related malnutrition is a frequently encountered yet both underrecognized and understudied clinical phenomenon in patients with NETs, with substantial prognostic and socioeconomic consequences. Most of these conditions can be alleviated by a tailored nutritional approach, also with the aim of improving the efficacy of cancer treatments. In this setting, skilled nutritionists can play a fundamental role in the multidisciplinary health care team in NETs management and their presence should be recommended.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • patients with neuroendocrine tumours (NETs)
Exclusion Criteria
  • age>65 years
  • < BMI 19 kg/m2
  • vegetarians

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adherence to Mediterranean Diet by Predimed QuestionnaireDecember 2017 to June 2018

Validated 14-item tool of adherence to the Mediterranean diet, with three categories of adherence (≤5, low adherence, 6-9, average adherence and ≥10 points, high adherence)

Secondary Outcome Measures
NameTimeMethod
Body compositionDecember 2017 to June 2018

BIA was performed using a BIA phase-sensitive system by experienced observers (an 800-µA current at a frequency single-frequency of 50 kHz BIA 101 RJL, Akern Bioresearch, Florence, Italy)

Trial Locations

Locations (1)

Silvia Savastano

🇮🇹

Naples, Italy

Silvia Savastano
🇮🇹Naples, Italy
© Copyright 2025. All Rights Reserved by MedPath